Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Leases (2019 - 2025)

Cytokinetics (CYTK) has disclosed Current Leases for 7 consecutive years, with $19.1 million as the latest value for Q4 2025.

  • Quarterly Current Leases changed N/A to $19.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $19.1 million for FY2025, N/A changed from the prior year.
  • Current Leases for Q4 2025 was $19.1 million at Cytokinetics, down from $20.6 million in the prior quarter.
  • The five-year high for Current Leases was $20.6 million in Q3 2025, with the low at $3.7 million in Q1 2021.
  • Average Current Leases over 5 years is $15.9 million, with a median of $16.1 million recorded in 2022.
  • Peak annual rise in Current Leases hit 433.68% in 2021, while the deepest fall reached 26.44% in 2021.
  • Over 5 years, Current Leases stood at $14.9 million in 2021, then fell by 13.68% to $12.8 million in 2022, then skyrocketed by 39.46% to $17.9 million in 2023, then increased by 5.39% to $18.9 million in 2024, then rose by 1.35% to $19.1 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $19.1 million, $20.6 million, and $19.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.